Fig. 6: LC-1–40 elicits MYC-driven synthetic lethality.
From: Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability
a Cell death analysis of SHEP MYCN-ER cells treated with LC-1-40 (50 nM) in the presence of 4-OHT (200 nM) and/or NAC (100 µM). b Cell death analysis of indicated tumor cells treated with LC-1-40. c Cell death analysis of primary neuroblastoma cells isolated from T423 (MYCN nonamplified) and T409 (MYCN-amplified) in the presence of LC-1-40 (100 nM). d Graphical illustration of neuroblastoma PDX and treatment strategy (see Materials and Methods for details). Mice were subjected to LC-1-40 (30 mg/kg) or vehicle treatment once daily. e Immunoblot of NUDT1 in T423 xenograft tumors isolated from NPG mice treated with vehicle or LC-1-40 (30 mg/kg, i.p.). Two tumors from each treatment group were used for the immunoblots. f–i Tumor growth and weights of T423 xenografts after 19-day treatment (f, g) or T409 xenografts after 15-day treatment (h, i) with vehicle or LC-1-40 (30 mg/kg). Five tumors were analyzed in each group. a–c data shown as averages of technical triplicates; a–c, e these experiments were independently repeated three times with similar results. Statistical significance was determined by unpaired two-tailed Student’s t-test (c, g, i) or two-way ANOVA (a, f, h). Source data are provided as a Source Data file.
